The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...

Adding afuresertib to paclitaxel did not improve outcomes in patients with platinum-resistant ovarian cancer in a phase 2 trial.

Corcept Therapeutics (CORT) announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Mid-cap stocks surged in the past week, including CORT, COOP, and CRWV. GOOG may rent AI servers from CRWV. PRGS and LOAR ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

Mirvetuximab soravtansine improved overall survival, progression-free survival, second progression-free survival, and other outcomes.

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

A new drug combination from Corcept Therapeutics, relacorilant, has shown potential in treating platinum-resistant ovarian ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...

Corcept Therapeutics Incorporated’s CORT share price has dipped by 19.51%, which has investors questioning if this is right time to buy.

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.